Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Maxcyte (MXCT) Gross Profit (2020 - 2025)

Maxcyte (MXCT) has disclosed Gross Profit for 6 consecutive years, with $5.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Gross Profit fell 16.08% to $5.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $27.5 million, a 29.79% decrease, with the full-year FY2024 number at $31.5 million, down 13.73% from a year prior.
  • Gross Profit was $5.2 million for Q3 2025 at Maxcyte, down from $7.0 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $14.1 million in Q4 2023 to a low of $5.2 million in Q3 2025.
  • A 5-year average of $8.3 million and a median of $8.5 million in 2022 define the central range for Gross Profit.
  • Peak YoY movement for Gross Profit: surged 81.4% in 2022, then plummeted 54.5% in 2024.
  • Maxcyte's Gross Profit stood at $8.9 million in 2021, then grew by 21.86% to $10.9 million in 2022, then rose by 29.56% to $14.1 million in 2023, then tumbled by 54.5% to $6.4 million in 2024, then fell by 18.39% to $5.2 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Gross Profit are $5.2 million (Q3 2025), $7.0 million (Q2 2025), and $8.9 million (Q1 2025).